// App-Quantinova.ai

1664 : Inhibition of Autophagy in Combination with Ponatinib or Dual PI3K/mTOR Inhibition to Improve Treatment Response for Both Bcr-Abl Dependent and Independent Mechanisms of TKI-Resistance in CML

Researchers

Presenter

  • Elaine K Allan

Principal Investigators

  • Samanta Mariani

  • Bruno Calabretta

  • Tessa L. Holyoake

  • Arunima Mukhopadhyay

  • Maria Karvela

  • Sara Galavotti

  • Alessandra Audia

  • Ashley Hamilton

  • Franck E. Nicolini

  • Brian J. Druker

  • Paolo Salomoni

Medical Centers

  • Hopital Edouard Herriot, Lyon, France

  • The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

  • Paul O?Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, United Kingdom

  • Samantha Dickson Brain Cancer Unit, UCL Cancer Institute, London, United Kingdom

Locations

  • France

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Cluster of Differentiation 34

  • Protein Tyrosine Phosphatase, Non-Receptor Type 11

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Hydroxychloroquine

  • Ponatinib

  • Rapacan

  • Imatinib

  • IkT001

  • L-Tyrosine

  • BEZ235

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • NCT01227135

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved